JLK

JLK EBITDA per Share

The EBITDA per Share of JLK (322510.KQ) as of Nov 3, 2026 is -476.67 KRW. In the previous year, EBITDA per Share was -357.04 KRW — a change of 33.51% (lower).

EBITDA per Share

-476.67KRW

YoY

33.51%

Last updated:

EBITDA per Share of JLK is 2024 -476.67 KRW. EBITDA per Share of JLK was 2023 -357.04 KRW. It decreases by 33.51% lower compared to the previous year.

The JLK EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2017
-483.58 KRW
Jan 1, 2018
-393.65 KRW
Jan 1, 2019
-687.64 KRW
Jan 1, 2020
-452.13 KRW
Jan 1, 2021
-425.70 KRW
Jan 1, 2022
-523.64 KRW
Jan 1, 2023
-357.04 KRW
Jan 1, 2024
-476.67 KRW
The JLK EBITDA per Share history
YEAREBITDA per ShareYoY
-476.67KRW+33.51%
-357.04KRW-31.82%
-523.64KRW+23.01%
-425.70KRW-5.85%
-452.13KRW-34.25%
-687.64KRW+74.68%
-393.65KRW-18.60%
-483.58KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

JLK Stock analysis

What does JLK do? JLK, Inc. generates revenue through AI medical analysis solutions, AI industry and security analysis solutions, and AI medical diagnostic platforms. The company's products include AI medical systems, AI quantitative analysis platforms, and AI remote platforms, which are sold to healthcare providers and medical institutions. The primary customer segments are hospitals and clinics seeking advanced diagnostic tools for brain disease detection. Revenue streams are derived from software licensing and subscription services for these AI-driven diagnostic systems. JLK, Inc. focuses on developing AI-based data-driven diagnostic systems specifically for brain disease detection. The company's AI medical diagnostic platforms are designed to provide accurate and efficient analysis for medical professionals. These platforms are part of the broader suite of AI medical analysis solutions that include AI quantitative analysis and AI remote platforms. The firm's target market includes healthcare facilities requiring cutting-edge technology for neurological diagnostics. The company's software products, such as AI medical systems and AI quantitative analysis platforms, are marketed to healthcare institutions for integration into their diagnostic workflows. Revenue is primarily generated through licensing agreements and recurring subscription fees for access to the AI-driven diagnostic tools. These solutions are positioned as essential for modern healthcare providers aiming to enhance diagnostic accuracy and patient outcomes in brain disease detection. JLK is one of the most popular companies on Eulerpool.

Frequently Asked Questions about JLK stock

EBITDA per Share of JLK is -476.67 KRW in 2024.

EBITDA per Share of JLK changed from -357.04 KRW to -476.67 KRW, representing a 33.51% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share JLK since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — JLK

All Key Metrics — JLK